Already have an account? Sign in.
Evercore ISI Initiates Street-High Price Target for CoreWeave
CoreWeave received an Outperform rating and a $175 price target from Evercore ISI.
CoreWeave received an Outperform rating and a $175 price target from Evercore ISI.
HSBC upgrades Nio to Buy from Hold, raises PT to $6.80 citing Q4 profit, stronger 2026 volume growth & margin upside.
Raymond James upgrades Korro Bio to Outperform from Market Perform with $23 PT, bullish on pivot to hyperammonemia programs in UCDs & HE with strong preclinical data and high unmet need.
Immutep’s key Phase 3 trial for its cancer drug efti was stopped early due to poor results. Analysts from Citizens and Baird downgraded the stock.